60 DEGREES PHARMACEUTICALS, INC.
No SEC Form 4 filings for $SXTP in the last 30 days.
See all $SXTP insider activity →60 Degrees Pharmaceuticals (SXTP) will unblind its hospitalized babesiosis study after enrolling 30 patients. The company expects results in January 2027 and plans to discuss regulatory pathways with the FDA. No safety signals were identified, and an expanded-access study supports potential molecular cures.
60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tafenoquine for Severe Babesiosis Study Interim Data Readout Webinar October 6, 2026 Today's discussion • Clinical context and current standard of care • Published evidence supporting tafenoquine + atovaquone • Hospital study interim analysis and DSMB feedback • Next
60 Degrees Pharmaceuticals (SXTP) shares rose 18% ahead of interim data release from its Phase 2 study of tafenoquine for severe babesiosis. The study, involving at least 24 patients, evaluates tafenoquine with standard care. No FDA-approved treatment exists for babesiosis, a tick-borne disease. SXTP's stock traded between $0.84 and $8.62 in the past year, closing Monday at $1.44.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning SXTP (60 DEGREES PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 6 neutral, and 0 bearish.
Recent SXTP coverage spans financial news, corporate actions and technology.
Unblinding the trial provides the first readout of efficacy and safety, which could drive the stock sharply up or down depending on outcomes.
Interim results show 4 of 5 patients achieved definitive clearance with tafenoquine‑containing regimens, indicating promising efficacy.
The upcoming data release could drive short-term volatility, with upside potential if results are positive.
The upcoming interim data could cause short-term volatility depending on the results.
Shareholder approvals raise near-term execution risk and potential dilution/price-volatility around the planned reverse split and equity plan expansion.
AlphAI scores every news story that mentions SXTP with an AI model for sentiment and relevance, and aggregates insider trades from 60 DEGREES PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
60 Degrees Pharmaceuticals (SXTP) will unblind its hospitalized babesiosis study after enrolling 30 patients. The company expects results in January 2027 and plans to discuss regulatory pathways with the FDA. No safety signals were identified, and an expanded-access study supports potential molecular cures.
2 min read60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tafenoquine for Severe Babesiosis Study Interim Data Readout Webinar October 6, 2026 Today's discussion • Clinical context and current standard of care • Published evidence supporting tafenoquine + atovaquone • Hospital study interim analysis and DSMB feedback • Next
2 min read60 Degrees Pharmaceuticals (SXTP) shares rose 18% ahead of interim data release from its Phase 2 study of tafenoquine for severe babesiosis. The study, involving at least 24 patients, evaluates tafenoquine with standard care. No FDA-approved treatment exists for babesiosis, a tick-borne disease. SXTP's stock traded between $0.84 and $8.62 in the past year, closing Monday at $1.44.
1 min read60 Degrees Pharmaceuticals (SXTP) will release interim data from its clinical study of tafenoquine for severe babesiosis on October 6, 2026. The company will host a webinar featuring experts Dr. Peter Krause and Dr. Edouard Vannier to discuss the results and potential of tafenoquine in treating babesiosis. No FDA-approved treatment exists for this disease.
2 min read60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 5, 2026, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), held its virtual 2026 Annual Stockholders Meeting (the “Meeting”). As of the close of business on July 2, 2026, the record d
2 min read60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules WASHINGTON, July 30, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that de
6 min read60 Degrees Pharmaceuticals (SXTP) said it agreed to a Nasdaq-priced at-the-market private placement. It will sell 574,713 shares (or pre-funded warrants) at $1.74 per share, with Series A warrants and Series B warrants exercisable at $1.49. Gross proceeds are about $1.0 million. Net proceeds will fund working capital. Closing expected around July 31, 2026.
3 min read60 Degrees Pharmaceuticals (SXTP) said it signed an exclusive option agreement with Florida State University Research Foundation covering IP for Castanospermine to target multiple tick-borne diseases, including Powassan virus, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease. The option allows SXTP to negotiate an exclusive U.S. license. The company cited preclinical antiviral and immunomodulatory activity and prior human safety experience from Celgosivir.
3 min read60 Degrees Pharmaceuticals (NASDAQ: SXTP; SXTPW) said it signed an exclusive option agreement with Florida State University Research Foundation to negotiate an exclusive U.S. license for castanospermine IP. The compound would be evaluated for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease, with an evaluation period to plan commercialization.
4 min readDOW GEOFFREY S (President and CEO) purchased 7,350 shares of 60 DEGREES PHARMACEUTICALS, INC. (SXTP) at $1.38 on 2026-06-12.
1 min read
